FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 499 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Revumenib for Relapsed or Refractory Acute Myeloid Leukaemia with a Susceptible NPM1 Mutation Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC EMA Recommends Extension of Indications for Sugemalimab MOST POPULAR What to Know About Biomarker Testing for Lung Cancer: An Expert... June 9, 2022 Cancer clinical trials – learning lessons from the COVID-19 pandemic May 19, 2021 Extended Follow-Up Further Supports Lenvatinib Plus Pembrolizumab in Patients with Previously... April 20, 2023 Learning to Advocate for Yourself – An Important Skill! June 15, 2023 Load more HOT NEWS Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... ESMO Immuno-Oncology Congress 2024, Geneva, Switzerland, 11-13 December Pyrotinib in HER2-mutated Advanced NSCLC Previously Treated with Chemotherapy Sugar Compound Found in Breast Milk May Help Ease Chemotherapy Side...
